Skip to content
MedsAcross

Medicine

Mexiletine 250 mg capsule

Mexiletine · Oral
Available on requestPrescription onlyUS FDAGeneric name

Mexiletine 250 mg capsule is a generic prescription medicine for oral use, made by 13 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20° to 25°C (68° to 77°F).

Key facts

Active ingredient (INN)
Mexiletine
Brand
Sold under the generic name
Strength
250 mg
Dosage form
Capsule
Route
Oral
Packs
100 capsules, 10 blister pack, 90 capsules and 14 more
Manufacturers
Macleods PharmaceuticalsIndiaCamber PharmaceuticalsIndiaSenores PharmaceuticalsIndiaSun Pharmaceutical IndustriesIndiaBryant Ranch PrepackAmerisynANI PharmaceuticalsAvKAREChartwell RXGolden State Medical Supply
Origin register
US FDA, United States
Storage
Store at 20° to 25°C (68° to 77°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
C01BB02 Mexiletine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
5 June 1995
Identifiers
RxCUI 1362720, 1362706, 1362712DailyMed set ID e2c0430d-35ee-460c-b0d5-f117d43430c5, 0ff45dbf-b555-4f55-a286-98bfaea9ea29, c4a60f9e-fed1-4172-adc4-0be84ac65db9 +13NDC 72162-1774, 72162-1784, 82012-029 +13Application ANDA074450, ANDA214089, ANDA216463 +5

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
100 capsule in 1 bottle31722-038-01Camber PharmaceuticalsIndia9 November 2022
100 capsule in 1 container33342-557-11Macleods PharmaceuticalsIndia23 March 2026
10 blister pack in 1 carton / 10 capsule in 1 blister pack33342-557-12Macleods PharmaceuticalsIndia23 March 2026
100 capsule in 1 bottle82012-029-04Senores PharmaceuticalsIndia29 November 2021
100 capsule in 1 bottle62756-957-01Sun Pharmaceutical IndustriesIndia29 November 2021
100 capsule in 1 bottle87564-054-10Amerisyn6 August 2026
100 capsule in 1 bottle62559-822-01ANI Pharmaceuticals22 June 2020
90 capsule in 1 bottle62135-785-90Chartwell RX25 October 2023
100 capsule in 1 bottle50742-241-01Ingenus Pharmaceuticals26 January 2021
100 capsule in 1 bottle64980-668-01Rising Pharma Holdings5 February 2025
100 capsule in 1 bottle0093-8741-01Teva Pharmaceuticals5 June 1995
100 capsule in 1 bottle63629-1964-1Bryant Ranch Prepack14 January 2021
100 capsule in 1 bottle63629-9181-1Bryant Ranch Prepack22 February 2022
100 capsule in 1 bottle72162-1774-1Bryant Ranch Prepack25 March 2026
100 capsule in 1 bottle72162-1784-1Bryant Ranch Prepack4 April 2024
100 capsule in 1 bottle42291-626-01AvKARE9 July 2013
100 capsule in 1 bottle51407-381-01Golden State Medical Supply18 December 2020

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 30 December 1985Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Mexiletine

Clinical summary

Mexiletine is an antiarrhythmic indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. It is available as capsules for oral use. MedsAcross supplies Mexiletine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Mexiletine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Mexiletine 250 mg capsule for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.